SHENZHEN, China, July 9 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will report its financial results for the second quarter ended June 30, 2009 after the U.S. market closes on August 10, 2009. Mindray's management will hold an earnings conference call at 8:00 AM on August 11, 2009 U.S. Eastern Time (8:00 PM on August 11, 2009 Beijing/Hong Kong Time).
Dial-in details for the earnings conference call are as follows: Hong Kong: +852-3002-1672 U.S. Toll Free: +1-866-700-7477 International: +1-617-213-8840 Passcode for all regions: Mindray
A replay of the conference call may be accessed by phone at the following numbers until August 22, 2009.
U.S. Toll Free: +1-888-286-8010 International: +1-617-801-6888 Passcode: 7624 2299
Additionally, a live and archived webcast of this conference call will be available on the Investor Relations section of Mindray's website at http://www.mindray.com .
We are a leading developer, manufacturer and marketer of medical devices worldwide. We maintain global headquarters in Shenzhen, China, U.S. headquarters in Mahwah, New Jersey and multiple sales offices in major international markets. From our main manufacturing and engineering base in China and through our worldwide distribution network, we are able to supply internationally a broad range of products across three primary business segments, comprised of patient monitoring and life support products, in-vitro diagnostic products and medical imaging systems. For more information, please visit http://www.mindray.com .
For investor and media inquiries please contact: In the U.S.: FD Evan Smith, CFA Tel: +1-212-850-5606 Email: firstname.lastname@example.org John Capodanno Tel: +1-212-850-5705 Email: email@example.com In China: Mindray Medical International Limited Cathy Gao Tel: +86-755-2658-2518 Email: firstname.lastname@example.org
|SOURCE Mindray Medical International Limited|
Copyright©2009 PR Newswire.
All rights reserved